Concepedia

Publication | Open Access

Phase 3 Trial of Nemolizumab in Patients with Prurigo Nodularis

DOIFull Paper Access

135

Citations

21

References

2023

Year

Shawn G. Kwatra, Gil Yosipovitch, Franz J. Legat, Adam Reich, C. Paul, Dagmar Simon, Luigi Naldi, Charles Lynde, Marjolein de Bruin‐Weller, Walter K. Nahm,
New England Journal of Medicine

Abstract

Nemolizumab monotherapy significantly reduced the signs and symptoms of prurigo nodularis. (Funded by Galderma; ClinicalTrials.gov number, NCT04501679; EudraCT number, 2019-004789-17.).

References

YearCitations

Page 1